Reference Database

Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes.
Ostrov, David A
Alkanani, Aimon
McDaniel, Kristen A
Case, Stephanie
Baschal, Erin E
Pyle, Laura
Ellis, Sam
Pöllinger, Bernadette
Seidl, Katherine J
Shah, Viral N
Garg, Satish K
Atkinson, Mark A
Gottlieb, Peter A
Michels, Aaron W
The Journal of clinical investigation 2018 May 01;128: 1888-1902

Major histocompatibility (MHC) class II molecules are strongly associated with many autoimmune disorders. In type 1 diabetes (T1D), the DQ8 molecule is common, confers significant disease risk, and is involved in disease pathogenesis. We hypothesized that blocking DQ8 antigen presentation would provide therapeutic benefit by preventing recognition of self-peptides by pathogenic T cells. We used the crystal structure of DQ8 to select drug-like small molecules predicted to bind structural pockets in the MHC antigen-binding cleft. A limited number of the predicted compounds inhibited DQ8 antigen presentation in vitro, with 1 compound preventing insulin autoantibody production and delaying diabetes onset in an animal model of spontaneous autoimmune diabetes. An existing drug with a similar structure, methyldopa, specifically blocked DQ8 in patients with recent-onset T1D and reduced inflammatory T cell responses to insulin, highlighting the relevance of blocking disease-specific MHC class II antigen presentation to treat autoimmunity.

Forward to a friend